缩写名/全名 |
BLOOD CANCER J
Blood Cancer Journal |
||||||||||||||||||||
ISSN号 | 2044-5385 | ||||||||||||||||||||
研究方向 | ONCOLOGY- | ||||||||||||||||||||
影响因子 | 2015:4.411, 2016:6.126, 2017:8.125, 2018:7.895, 2019:8.023, | ||||||||||||||||||||
出版国家 | ENGLAND | ||||||||||||||||||||
出版周期 | |||||||||||||||||||||
年文章数 | 65 | ||||||||||||||||||||
出版年份 | 2011 | ||||||||||||||||||||
是否OA | Yes | ||||||||||||||||||||
审稿周期(仅供参考) | >12周,或约稿 |
||||||||||||||||||||
录用比例 | 容易 | ||||||||||||||||||||
投稿链接 | http://mts-bcj.nature.com/cgi-bin/main.plex | ||||||||||||||||||||
投稿官网 | http://www.nature.com/bcj/index.html | ||||||||||||||||||||
h-index | 37 | ||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2044-5385%5BISSN%5D | ||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | High expression of PTPN21 in B-cell non-Hodgkin's gastric lymphoma, a positive mediator of STAT5 activity. Author: Plani-Lam JH, Chow TC, Fan YH, Garcia-Bloj B, Cheng L, Jin DY, Hancock W, Fanayan S, Ingley E, Song YQ. Journal: Blood Cancer J. 2016 Jan 15;6:e388. doi: 10.1038/bcj.2015.107. No abstract available. PubMed |
2. | Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study. Author: Lu A, Fang Y, Du X, Li Y, Cai Z, Yu K, Zhao L, Wang B, Wu J, Cheng Y, Zuo Y, Jia Y, Tan F, Ding L, Lu J, Zhang L, Huang X. Journal: Blood Cancer J. 2016 Feb 26;6:e400. doi: 10.1038/bcj.2016.8. No abstract available. PubMed |
3. | The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor. Author: Wu R, Sattarzadeh A, Rutgers B, Diepstra A, van den Berg A, Visser L. Journal: Blood Cancer J. 2016 May 6;6:e417. doi: 10.1038/bcj.2016.26. No abstract available. PubMed |
4. | Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Author: Chen Z, Wang W, Cortes JE, Liu E, Miranda RN, Zhao C, Yuan J, Lu X, Yang W, Ameri MD, Kantarjian HM, Medeiros LJ, Hu S. Journal: Blood Cancer J. 2016 May 6;6:e418. doi: 10.1038/bcj.2016.27. No abstract available. PubMed |
5. | Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome. Author: Cher CY, Leung GM, Au CH, Chan TL, Ma ES, Sim JP, Gill H, Lie AK, Liang R, Wong KF, Siu LL, Tsui CS, So CC, Wong HW, Yip SF, Lee HK, Liu HS, Lau JS, Luk TH, Lau CK, Lin SY, Kwong YL, Leung AY. Journal: Blood Cancer J. 2016 Jul 8;6(7):e442. doi: 10.1038/bcj.2016.51. PubMed |
6. | Reprogramming of Notch1-induced acute lymphoblastic leukemia cells into pluripotent stem cells in mice. Author: Zhang H, Cheng H, Wang Y, Zheng Y, Liu Y, Liu K, Xu J, Hao S, Yuan W, Zhao T, Cheng T. Journal: Blood Cancer J. 2016 Jul 8;6(7):e444. doi: 10.1038/bcj.2016.57. No abstract available. PubMed |
7. | Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi- Author: huangxiaojun Journal: Blood Cancer Journal, 2016. |
8. | Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi- Author: zhangleping Journal: Blood Cancer Journal, 2016. |
9. | Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi- Author: jin1lu Journal: Blood Cancer Journal, 2016. |
|
|